Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention

Molecular Pharmacology

Volumn 74, Issue 5, 2008, Pages 1381-1391

  Hagos, Ghenet K ^a   Abdul Hay, Samer O ^a   Sohn, Johann ^a   Edirisinghe, Praneeth D ^a   Chandrasena, R Esala P ^a   Wang, Zhiqiang ^a   Li, Qian ^a   Thatcher, Gregory R J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2,3 BIS(NITROOXY)PROPYL]DISULFANYL]BENZOATE; BENZOIC ACID DERIVATIVE; GT 094; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CYTOPROTECTION; ENZYME INDUCTION; HUMANS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 54349129548     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.046664     Document Type: Article

References (51)

1. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, and Wallace JL (1998) Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 62:PL367-PL373.
2. Bolla M, Almirante N, and Benedini F (2005) Therapeutic potential of nitrate esters of commonly used drugs. Curr Top Med Chem 5:707-720.
3. Brannigan LH, Hodge RB, and Field L (1976) Biologically oriented organic sulfur chemistry. 14. Antiinflammatory properties of some aryl sulfides, sulfoxides, and sulfones. J Med Chem 19:798-802.
4. Bratasz A, Weir NM, Parinandi NL, Zweier JL, Sridhar R, Ignarro LJ, and Kuppusamy P (2006) Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci U S A 103:3914-3919.
5. Buckley BJ, Li S, and Whorton AR (2008) Keap1 modification and nuclear accumulation in response to S-nitrosocysteine. Free Radic Biol Med 44:692-698.
6. Buga GM, Wei LH, Bauer PM, Fukuto JM, and Ignarro LJ (1998) NG-Hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am J Physiol 275:R1256-R1264.
7. Chen C, Pung D, Leong V, Hebbar V, Shen G, Nair S, Li W, and Kong AN (2004) Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of chemical structure and stress signals. Free Radic Biol Med 37:1578-1590.
8. Chen C, Yu R, Owuor ED, and Kong AN (2000) Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 23:605-612.
9. Connelly L, Jacobs AT, Palacios-Callender M, Moncada S, and Hobbs AJ (2003) Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem 278:26480-26487.
10. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, and Hobbs AJ (2001) Biphasic regulation of NF-kappa B activity underlies the pro- and antiinflammatory actions of nitric oxide. J Immunol 166:3873-3881.
11. Corpet DE and Taché S (2002) Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 43:1-21.
12. Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duée PH, Martel P, and Chaumontet C (2004) Diallyl disulfide (DADS) increases histone acetylation and p21waf1/cip1 expression in human colon tumor cell lines. Carcinogenesis 25:1227-1236.
13. Dunlap T, Abdul-Hay SO, Chandrasena RE, Hagos GK, Sinha V, Wang Z, Wang H, and Thatcher GR (2008) Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality. Nitric Oxide 19:115-124.
14. Dunlap T, Chandrasena RE, Wang Z, Sinha V, Wang Z, and Thatcher GR (2007) Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. Chem Res Toxicol 20:1903-1912.
15. Ford PC, Wink DA, and Stanbury DM (1993) Autoxidation kinetics of aqueous nitric oxide. FEBS Lett 326:1-3.
16. Gao J, Kashfi K, Liu X, and Rigas B (2006) NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis 27:803-810.
17. Gao J, Liu X, and Rigas B (2005) Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci U S A 102:17207-17212.
18. Goldstein S, Russo A, and Samuni A (2003) Reactions of PTIO and carboxy-PTIO with *NO, *NO2, and O2-*. J Biol Chem 278:50949-50955.
19. Hagos GK, Carroll RE, Kouznetsova T, Li Q, Toader V, Fernandez PA, Swanson SM, and Thatcher GRJ (2007) Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo. Mol Cancer Ther 6:2230-2239.
20. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, and Jansen B (2000) A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 6:693-704.
21. Hao XP, Pretlow TG, Rao JS, and Pretlow TP (2001) Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 61:419-422.
22. Hinz B, Brune K, and Pahl A (2000) Nitric oxide inhibits inducible nitric oxide synthase mRNA expression in RAW 264.7 macrophages. Biochem Biophys Res Commun 271:353-357.
23. Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, de Esch IJ, Richel D, and Wijtmans M (2007) Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 50:2424-2431.
24. Kang YH and Pezzuto JM (2004) Induction of quinone reductase as a primary screen for natural product anticarcinogens. Methods Enzymol 382:380-414.
25. Kapadia GJ, Azuine MA, Takayasu J, Konoshima T, Takasaki M, Nishino H, and Tokuda H (2000) Inhibition of Epstein-Barr virus early antigen activation promoted by 12-O-tetradecanoylphorbol-13-acetate by the non-steroidal antiinflammatory drugs. Cancer Lett 161:221-229.
26. Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, and Rigas B (2005) Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 312:978-988.
27. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B, and Ryann Y (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 303:1273-1282.
28. Kaza CS, Kashfi K, and Rigas B (2002) Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat 67:107-120.
29. Knowles LM and Milner JA (2003) Diallyl disulfide induces ERK phosphorylation and alters gene expression profiles in human colon tumor cells. J Nutr 133:2901-2906.
30. MacNaughton WK, Cirino G, and Wallace JL (1989) Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 45:1869-1876.
31. Maragos CM, Morley D, Wink DA, Dunams TM, Saavedra JE, Hoffman A, Bove AA, Isaac L, Hrabie JA, and Keefer LK (1991) Complexes of ̇NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem 34:3242-3247.
32. Munday R and Munday CM (2004) Induction of phase II enzymes by aliphatic sulfides derived from garlic and onions: an overview. Methods Enzymol 382:449-456.
33. Nicolescu AC, Li Q, Brown L, and Thatcher GRJ (2006) Nitroxidation, nitration, and oxidation of a BODIPY fluorophore by RNOS and ROS. Nitric Oxide 15:163-176.
34. Nicolescu AC, Zavorin SI, Turro NJ, Reynolds JN, and Thatcher GRJ (2002) Inhibition of lipid peroxidation in synaptosomes and liposomes by nitrates and nitrites. Chem Res Toxicol 15:985-998.
35. Prestera T and Talalay P (1995) Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci U S A 92:8965-8969.
36. Prochaska HJ and Santamaria AB (1988) Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 169:328-336.
37. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, and Rigas B (2006) Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 5:1530-1538.
38. Rosenberg L, Louik C, and Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82:2326-2333.
39. Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, and Moher D (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:376-389.
40. Song LL, Kosmeder JW 2nd, Lee SK, Gerhäuser C, Lantvit D, Moon RC, Moriarty RM, and Pezzuto JM (1999) Cancer chemopreventive activity mediated by 4′-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res 59:578-585.
41. Sumiyoshi H and Wargovich MJ (1990) Chemoprevention of 1,2-dimethylhydrazine-induced colon cancer in mice by naturally occurring organosulfur compounds. Cancer Res 50:5084-5087.
42. Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, and Miyata N (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J Med Chem 49:4809-4812.
43. Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, and Zoli W (2003) NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Int J Oncol 22:1297-1302.
44. Thatcher GRJ (2007) Organic nitrates and nitrites as stores of NO, in Radicals for Life: The Various Forms of Nitric Oxide (van Fassen E and Vanin A eds), Elsevier Science, Amsterdam, The Netherlands.
45. Thatcher GR, Nicolescu AC, Bennett BM, and Toader V (2004) Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radic Biol Med 37:1122-1143.
46. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, and Wink DA (2004) Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A 101:8894-8899.
47. Wang D and Dubois RN (2006) Prostaglandins and cancer. Gut 55:115-122.
48. Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, and Kelloff GJ (1996) Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5:355-360.
49. Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, and Rigas B (2003) Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 63:7613-7618.
50. Yang P, Felix E, Madden T, Fischer SM, and Newman RA (2002) Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem 308:168-177.
51. Zhang DD and Hannink M (2003) Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23:8137-8151.